Paris, September 4, 2007 - BioAlliance Pharma SA (Euronext Paris: FR0010095596 - BIO), a specialty pharmaceutical company focused on the development of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, announced today the launch of its first drug, Loramyc®, on the French market.
BioAlliance Pharma is the first biotech company in France to have successfully managed the whole process of bringing an academic innovation out of the lab, through R&D and onto the market.
Loramyc® is available on the French market as of today at pharmacies and healthcare establishments, following the official publication of its approval for use in hospitals as well as details of reimbursement by French health authorities.
Loramyc® is a drug specifically developed for Oropharyngeal Candidiasis in immunodepressed patients, who frequently suffer an associated mucositis. It offers an optimized anti-fungal treatment with the same level of activity as systemic therapies, with the advantage that it specifically targets the mouth and the oropharynx.
The new therapeutic approach uses an innovative delivery system based on a mucoadhesive buccal tablet. This ensures an early and extended release of the active component at the site of the infection, with only one dose per day.
"Our team of scientific sales representatives report that hospital oncology and infection specialists have shown a lot of interest in Loramyc®, which responds to an unmet medical need," said Florence Dupre, VP Sales & Marketing at BioAlliance Pharma.
"This launch is a key step for BioAlliance Pharma and marks the first phase in our international deployment. In fact, the agreements concluded this year are enabling us to build a stronger market presence with Loramyc® in Europe, through our SpeBio Joint Venture, and in the US, through our licensing partnership with Par Pharmaceutical," said Dominique Costantini, President and CEO of BioAlliance Pharma.
About BioAlliance Pharma
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting drug resistance in cancer, HIV, and opportunistic infections.
The Company is conducting clinical development of three innovative products. Two products are based on the Lauriad® mucoadhesive technology, which allows an early and prolonged release of therapeutic agents at the site of the disease: one authorized product in France and two clinical international phase III trials ongoing (Loramyc® and aciclovir Lauriad®). One product is based on the Transdrug® nanoparticle technology designed specifically for intracellular targeting: one international phase III trial ongoing on primary liver cancer (doxorubicin Transdrug®). The company develops also a New Entities program focused on new targets in oncology and HIV. The company has concluded two strategic partnerships in 2007 to sell its Loramyc® product in Europe and in the US.Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website www.amf-france.org or BioAlliance Pharma S.A.'s website www.bioalliancepharma.com.
For press release and other company information, visit www.bioalliancepharma.com.
|BioAlliance Pharma SA|
President and CEO
Tel: +33 1 45 58 76 01
Chief Financial Officer
Tel: +33 1 45 58 71 00
Tel : +33 1 53 67 36 33
Andrew Lloyd & Associates
Tel: +33 1 56 54 07 00
| Juliette DOS SANTOS
Tel : +33 1 56 54 07 04
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|ONXEO||Euronext Paris||2.69 (c)||-0.37%||60 966|